AzTrials
AzTrials

Brain HealthAAAgingNCT07466290

L-serine and Strength Training in the Elderly

A study testing Strength training and L-serine supplementation in people with Brain Health and Longevity, run by University of Vienna at 1 site in Austria.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people. Healthy, independent women and men aged 65 to 85 are eligible to participate. Read more about this study

Who is it for?
Ages 65 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Brain Health, Longevity, Cognitive Performance
What is being tested?
Strength training and L-serine supplementation
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
126 participants
Where
1 siteAustria
Study dates
Mar 2026to Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Older adult

Who may be able to join

  • Men and women between the ages of 65 and 85
  • Mini-Mental-State >23
  • Independently mobile, without aids (walker, cane, etc.)

Who cannot join

  • Chronic diseases that contraindicate medical training therapy
  • Regular strength training (>1x/week) in the last 6 months before confinement
  • Frailty Index ≥ 3
  • Lack of written consent to test physical performance
  • Regular use of Cortison-containing medications or Antibiotika
  • MR-specific exclusion criteria: claustrophobia, metal equipment or other magnetic Material in or on the body
  • Non-compliance with the study protocol: <70% of the planned L-serine administration, <70% of the strength training

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Karl-Heinz Wagner, Prof. contact

+43-1-4277-54930

karl-heinz.wagner@univie.ac.at

Austria1 site, 1 recruiting
  • NuTraLab

    Vienna, State of Vienna, 1070

    Recruiting

Other trials in Austria

About this study

This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people.

Healthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training.

Cognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The aim is to gain a better understanding of how nutrition and exercise can contribute to healthy aging.

Read the detailed description

The study is a randomized, controlled, double-blind intervention study with three parallel groups of healthy older adults (aged 65-85). It investigates the effects of L-serine supplementation with and without accompanying strength training on cognitive, neural, molecular, and functional parameters over 48 weeks.

The primary endpoint is the change in cognitive performance, measured using the composite RBANS score. Secondary endpoints include structural and functional brain parameters (MRI, EEG), psychosocial parameters, markers of oxidative stress and immune function, as well as physical performance and muscle mass.

Being tested
Strength training, L-serine supplementation, Control (cornstarch)
Keywords
Healthy Ageing, Brain ageing, Older adults, L-serine supplementation, Resistance training, Cognitive function, Cognitive ageing, Memory, Hippocampus, Magnetic resonance imaging, Electroencephalography, Brain connectivity, Muscle strength, Synaptic plasticity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Strength trainingBehavioural

    Structured strength training 2x/week

  • L-serine supplementationDietary supplement

    L-serine supplementation 6g/day

  • Control (cornstarch)Dietary supplement

    Placebo 6g cornstarch/day, No strength training

Study groups in NCT07466290
Study groupRoleWhat they receive
L-serine and strength trainingExperimentalThe L-serine and training group (LSERTRAIN) receives an L-serine supplement at a dose of 6 g/day over the entire study period (48 weeks).
Receives: Behavioral: Strength training; Dietary Supplement: L-serine supplementation
L-serine supplementationActive comparatorThe L-serine group (LSER) receives an L-serine supplement at a dose of 6 g/day over the entire study period (48 weeks).
Receives: Dietary Supplement: L-serine supplementation
ControlPlacebo comparatorThe control group (PLA) receives a placebo (cornstarch) throughout the entire study period (48 weeks)
Receives: Dietary Supplement: Control (cornstarch)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in cognitive performance measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    Global cognitive performance will be assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a standardized neuropsychological test battery that evaluates multiple cognitive domains including memory, attention, language, and visuospatial abilities.

    The primary outcome is the RBANS Total Scale Index score, which summarizes performance across the RBANS cognitive domains. RBANS index scores are standardized scores with a mean of 100 and a standard deviation of 15, typically ranging from approximately 40 to 160. Higher scores indicate better cognitive performance.

    Measured: Baseline, 18 weeks and 48 weeks of intervention

Secondary outcomes (30)
  1. Change in cognitive domain performance measured by index scores of RBANS

    The RBANS provides standardized index scores (mean = 100, standard deviation = 15) that typically range from approximately 40 to 160, with higher scores indicating better cognitive performance. The following RBANS domain indices will be evaluated: Immediate Memory Index, Visuospatial/Constructional Index, Language Index, Attention Index, and Delayed Memory Index.

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  2. Change in hippocampal volume measured by magnetic resonance imaging (mm³)

    Measured: Baseline and 48 weeks of intervention

  3. Change in hippocampal functional connectivity measured by functional magnetic resonance imaging

    Measured: Baseline and 48 weeks of intervention

  4. Change in oscillatory brain activity measured using electroencephalography

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  5. Change in hippocampal neurometabolite concentrations measured using single voxel magnetic resonance spectroscopy

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  6. Change in lower limb muscle strength (isokinetic torque, dominant leg)

    Concentric isokinetic peak torque (in newton meters, Nm) will be assessed for knee extension, knee flexion, and hip extension and flexion using an Isoforce dynamometer (TUR GmbH, Hohen Neuendorf, Berlin).

    All isokinetic measurements will be performed on the dominant leg and with 4 consecutive repetitions at maximal effort of extension and flexion.

    Testing the knee will be performed over a range of motion (ROM) of 20 degrees-100 degrees at angular velocities of 60 degrees/s , and 180 degrees/s.

    Testing the hip will be performed over a range of motion (ROM) of 20 degrees- 90 degrees at angular velocities of 60 degrees/s , and 180 degrees/s.

    The minimum possible torque is 00 Nm; higher values indicate better muscle strength.

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  7. Rate of torque development (Nm/s) will be measured at a joint angle of 60 degrees flexion (knee) and 40 degrees flexion (hip).

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  8. Change in maximum and total work (J) of knee and hip flexion and extension

    Measured: Baseline, 18 weeks and 48 of intervention

  9. Position of peak torque and maximum range of motion (deg.)

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  10. Change in time to peak torque and time from peak to relaxation (sec.) during knee and hip extension and flexion

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  11. Mean power (W) in knee and hip extension and flexion

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  12. Change in isometric handgrip strength

    Isometric handgrip strength will be measured in kilograms (kg) using a JAMAR-compatible handgrip dynamometer adjustable to different grip widths. Testing will be performed seated. Each trial consists of a maximal isometric contraction held for 4-5 seconds; two trials will be conducted with the dominant and subsequently with the non-dominant hand, with 1-2 minutes rest between trials. The minimum possible value is 00 kg; higher values indicate better grip strength. Results will be recorded per trial; the analysis will use the highest value from the two trials (peak grip strength, kg).

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  13. Change in upper extremity functional performance measured by the 30-Second Arm Curl Test

    The 30-Second Arm Curl Test assesses the number of full elbow-flexion repetitions completed in 30 seconds with a standardized dumbbell while seated.

    Women use a 5 lb (2.3 kg) dumbbell; men use an 8 lb (3.6 kg) dumbbell. Participant sits upright near the front edge of a chair without armrests, back straight, feet flat on the floor, holding the dumbbell in the dominant hand with a supinated grip. After instruction and demonstration, the participant performs 2-3 practice repetitions. Following a 60-second rest, the timed test begins on the assessor's signal. The starting position is full elbow extension (down); the end position is full elbow flexion (up). Count only repetitions that complete the full range of motion (ROM). A repetition initiated in the final second (second 30) is counted as valid if more than 50% of the ROM is completed.

    Minimum possible value is 0 repetitions; there is no predefined maximum.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  14. Change in upper-body flexibility (Back Scratch Test)

    The Back Scratch Test assesses shoulder, shoulder-girdle, and thoracic spine flexibility. While standing, one hand is placed over the shoulder and down between the shoulder blades; the other hand reaches up the back. The linear distance between the tips of the middle fingers is measured along the spine using a tape measure.

    Record the distance in centimeters (cm) with sign convention: positive values indicate fingertip overlap; zero indicates fingertips just touch; negative values indicate a gap between fingertips. There is no predefined minimum or maximum (values can range from negative to positive depending on flexibility and anthropometrics). Higher (more positive) values indicate better flexibility.

    Back Scratch distance (cm), dominant side (specify side assessed in the protocol). Use the same side and method at all time points.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  15. Change in Lower body flexibility (Chair Sit and Reach Test)

    The participant sits at the front edge of a stable chair placed against a wall (seat height approximately 45-46 cm). One leg is flexed at the knee with the foot flat on the floor; the other leg is extended at the knee with the ankle dorsiflexed to approximately 90 degrees. With the hands stacked (middle fingertips aligned), the participant inhales, then exhales while hinging at the hips to reach forward toward the toes of the extended leg, avoiding bouncing; the back stays straight and the head upright. The maximal position is held for about 2 seconds. The linear distance between the tip of the middle finger and the toes of the extended leg is measured along the lower limb/foot.

    Record the distance (cm) using the following convention-0 cm if fingertips just touch the toes; negative values if the fingertips do not reach the toes (gap); positive values if the fingertips reach past the toes (overlap). Perform two trials per leg; record the best value per leg.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  16. Change in lower extremity functional muscular performance measured by the 30-Second Chair Stand Test

    The 30-Second Chair-Stand Test assesses functional muscular performance (strength × speed) of the lower extremities.

    Stable, armless chair at approximately 46 cm seat height, placed against a wall to prevent movement. Participants wear non-slip, flat footwear or are barefoot. Participant sits upright, feet flat on the floor, arms crossed over the chest. On the assessor's signal, the participant stands up fully (knee and hip extension) and sits down as many times as possible within 30 seconds without using the arms. Count only full stand-sit cycles completed through the full range of motion (ROM). A repetition initiated in the final second (second 30) is counted as valid if more than 50% of the ROM is completed.

    Number of valid chair-stands completed in 30 seconds. Minimum possible value is 0 repetitions; there is no predefined maximum. Higher values indicate better lower-extremity functional performance.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  17. Mobility and dynamic balance (Stand Up and Go Test)

    The Stand Up and Go Test assesses dynamic lower extremity power, dynamic balance, and overall functional mobility/coordination.

    Stable chair placed against a wall, seat height approximately 43 cm; a cone/marker placed 2.4 m from the front edge of the chair; clear, unobstructed path.

    Participant starts seated, back upright, feet flat on the floor. On the assessor's signal, the participant stands up, walks 2.4 m to the cone, turns around the cone, walks back to the chair, and sits down again. Timing begins on the start signal and stops when the participant is fully seated. Testing is performed in usual footwear; use of any assistive device (if permitted) should be consistent across visits and recorded.

    Time to complete the task, measured in seconds (s) to at least 0.1 s precision. Minimum possible value is 0 s; there is no predefined maximum. Lower times indicate better mobility and balance (i.e., higher values indicate worse performance).

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  18. Change in body composition measured by bioelectrical impedance analysis

    Body composition will be assessed using bioelectrical impedance analysis (seca Hamburg seca mBCA515), including measures of fat mass, lean body mass, body mass, and body water .

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  19. Change in waist, abdominal, hip circumference (cm)

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  20. Change in oxidative stress marker such as malondialdehyde

    The investigators will consider changes in plasma concentrations of oxidative stress marker such as malondialdehyde.

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  21. Change from baseline in inflammatory marker (e.g. IL-6, TNF-alpha)

    The investigators will consider changes in plasma concentrations of inflammatory markers such as Interleukin 1 (IL-1), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  22. Change from baseline in RNA and DNA gene expression

    RNA and DNA gene expression will be assessed in response to the interventions.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  23. Change from baseline in chromosomal damage (number of micronuclei/1000 binucleated cells)

    Chromosomal damage will be assessed in lymphocytes in response to the interventions.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  24. Change from baseline in the composition of gut-microbiota

    Gene sequencing of the 16S rRNA on the stool samples are performed to identify the microbes down to genus level as well as the microbial diversity and relative abundance.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  25. Change from baseline in stool short-chain fatty acids (SCFAs)

    The stool short-chain fatty acids (SCFAs) will be extracted and quantitatively analysed by gas chromatography.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  26. Change from baseline in the metabolomic response

    The metabolomic response (ie all metabolites) to the interventions will be analyzed using both nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques. Patterns of metabolites will be evaluated with statistical techniques, ie discriminant analysis and principal component analysis.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  27. Change from baseline in the amino acid pattern

    The plasma amino acid pattern will be assessed with HPLC-MS.

    Measured: Baseline, 18 weeks, and 48 weeks of intervention

  28. Nutritional habits

    Evaluation of potential changes in nutritional habits (24 hours dietary recall) with GloboDiet

    Measured: Baseline, 18 weeks and 48 weeks of intervention

  29. Change in sleep quality measured by the Pittsburgh Sleep Quality Index

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. The PSQI global score ranges from 0 to 21, with higher scores indicating worse sleep quality.

    Measured: Baseline, 18 weeks, and 48 weeks

  30. Change in quality of life measured by the World Health Organization Quality of Life Questionnaire

    Quality of life will be assessed using the World Health Organization Quality of Life Questionnaire (WHOQOL). Scores range from 0 to 100, with higher scores indicating better perceived quality of life.

    Measured: Baseline, 18 weeks, and 48 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2026
  2. Study startMar 2026 (estimated)
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
126 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07466290
Sponsor's protocol ID
01391
Other IDs
10.55776/PIN359
Acronym
AAAging
Status last verified
Feb 2026
First submitted
23 Feb 2026
Last updated
12 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Strength training and L-serine supplementation in people with Brain Health and Longevity, run by University of Vienna at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Karl-Heinz Wagner, Prof. (+43-1-4277-54930, karl-heinz.wagner@univie.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in cognitive performance measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (time frame: Baseline, 18 weeks and 48 weeks of intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in